For how we live.
12 articles published between October 10, 2025 and September 2, 2026.
A network meta-analysis of 163 trials found EPA, vitamin D and a St John's wort extract beat placebo by margins so large the researchers treat them as a warning about the evidence, not a green light.
A 1.5-million-person records study reports lower mortality with GLP-1 drugs than with SGLT2 inhibitors, and the largest absolute gains in people with serious mental illness. The design cannot prove it.
Using causal-inference methods on 1,269 people, researchers linked two bacterial genera to depression independent of body weight and medication — the first such evidence in humans, not proof of mechanism.
The agency compressed review of three psychedelic therapies from a year to weeks. A first approval decision is plausible by early 2027.
A registry study spanning 4.9 million people separates where the most deaths occur from where the inequality is largest. Heart disease and lung disease give different answers.
By the study's end, 70% had scores low enough to be considered near-resolution. There was no placebo arm — every participant knew what they'd received.
In 35 patients with recurrent major depression, psilocybin beat an active placebo through day 42. On self-reported measures the effect lingered further, but the trial's primary endpoint showed no difference at 365 days.
The open-label pilot tested a specific worry in psychedelic research — that borderline personality disorder blunts response to psilocybin for depression. In this small sample, it didn't.
A pooled analysis of five trials in treatment-resistant depression found sex differences in response. The largest ones appeared in both arms, which points at something other than the drug.
In the RECOVER extension, about a fifth of participants were in remission at 24 months and some who had not responded at 12 months did later. The second year had no control group.
A within-individual analysis of 505,474 people in Finland and Sweden found lower psychiatric hospitalisation on clozapine in every disorder studied except borderline personality disorder, with no excess mortality signal.
Pooling 31 studies of 556 patients, cortical 5-HT2A binding was lower in unmedicated depression than in controls. The post-mortem studies mostly found nothing, and the tracers used shape the result.